Skip to main content

Table 2 Individual study characteristics

From: Genetic basis of cannabis use: a systematic review

First Author Last Name, Year Title of Publication Study Design Cohort used Sample Size % Male Mean age Ethnicity Outcome of interest
Agrawal, 2011 A Genome-wide Association Study of DSM-IV Cannabis Dependence Case–Control SAGE 3054 NR 39.00 2019 European-Americans, 1035 African Americans Life-time history of DSM-IV cannabis dependence, modified to included cannabis withdrawal
Agrawal, 2014 DSM-5 Cannabis Use Disorder: A Phenotypic and Genomic Perspective Case–control SAGE 3053 49% 38.10 2018 European-Americans, 1035 African Americans DSM-5 cannabis use disorder factor scores
Demontis, 2019 Genome-wide association study implicates CHRNA2 in cannabis use disorder Case-cohort iPSYCH CUD: 2387
Control: 48,985
Total: 51,372
NR CUD: 24.77
Control: 22.67
European International Statistical Classification of Disease and Related Health Problems, 10th revision (ICD-10) diagnosis reflecting problematic and persistent use of cannabis
Minica, 2015 Heritability, SNP- and Gene-Based Analyses of Cannabis Use Initiation and Age at Onset Cohort Netherlands twin registry 6744 39.1% 39.09 European Self-reported use of cannabis ever in lifetime and self-reported age of onset of cannabis use
Pasman, 2018 GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal effect of schizophrenia liability Cohort ICC study 35,297 44.3% 35.7 European Any cannabis use within lifetime
UK Biobank 126,785 43.7% 55
23andMe 22,683 NR NR
Sherva, 2016 Genome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic Risks Cohort/Case-cohort Yale-Penn, SAGE, ICGHD 14,754 53.4% 39.24 8754 European-American, 6000 African American Criterion count for DSM-IV Cannabis Dependence